Clinical trial
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease…
NCT00291902 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00291902 |
|---|---|
| Title | A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention |
| Official title | A 28-day, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Anti-inflammatory Effect and Steady-state Pharmacokinetics of SB-681323 (7.5 mg) in Subjects With Coronary Heart Disease (CHD) Undergoing Elective Percutaneous Coronary Interventions (PCI) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Heart Disease |
| Intervention type | Drug |
| Interventions | SB-681323 |
| Enrollment | 80 |
| Start date | Mar 1, 2006 |
| First posted | Feb 15, 2006 |
| Last update posted | Jun 4, 2012 |
| Countries | Denmark, Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: